Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.30
+0.02 (0.14%)
At close: Feb 6, 2026, 4:00 PM EST
14.28
-0.02 (-0.14%)
After-hours: Feb 6, 2026, 5:10 PM EST
Amicus Therapeutics Employees
Amicus Therapeutics had 499 employees as of December 31, 2024. The number of employees decreased by 18 or -3.48% compared to the previous year.
Employees
499
Change (1Y)
-18
Growth (1Y)
-3.48%
Revenue / Employee
$1,199,808
Profits / Employee
-$28,178
Market Cap
4.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 499 | -18 | -3.48% |
| Dec 31, 2023 | 517 | 33 | 6.82% |
| Dec 31, 2022 | 484 | -12 | -2.42% |
| Dec 31, 2021 | 496 | 13 | 2.69% |
| Dec 31, 2020 | 483 | -101 | -17.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ACADIA Pharmaceuticals | 654 |
| Corcept Therapeutics | 500 |
| Crinetics Pharmaceuticals | 437 |
| CRISPR Therapeutics AG | 393 |
| TG Therapeutics | 374 |
| Apogee Therapeutics | 196 |
| Arcellx | 163 |
| Scholar Rock Holding | 128 |
FOLD News
- 5 days ago - Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - GlobeNewsWire
- 6 days ago - Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
- 6 weeks ago - Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD - Business Wire
- 6 weeks ago - BioMarin: Amicus Buyout Sparks My Enthusiasm - Seeking Alpha
- 7 weeks ago - BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. - Barrons
- 7 weeks ago - BioMarin to Buy Amicus Therapeutics for $4.8 Billion - WSJ
- 7 weeks ago - BioMarin to acquire Amicus Therapeutics for $4.8 Billion - Reuters
- 7 weeks ago - BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - PRNewsWire